Turn Therapeutics Inc (TTRX)
NASDAQ:TTRX
TTRX Stock Chart & Stats
$2.74
--
Market closed
$2.74
--
Day’s Range― - ―
52-Week Range$2.57 - $26.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.86M
Market Cap
$99.79M
Enterprise Value$49.16M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.34
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,788,040
10 Day Avg. Volume2,856,380
30 Day Avg. Volume2,856,380
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)11.55
Price to Sales (P/S)0.00
P/FCF Ratio-19.94
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.15Price Target Upside124.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extended Runway Via Growth CapitalSecuring an upfront tranche and up-to-$25M facility materially lengthens financing runway, allowing the company to complete the Phase 2 readout and advance registrational planning. This reduces immediate financing pressure and preserves ability to execute clinical milestones that create lasting value.
Commercial Partnership To Drive Early RevenueA commercial agreement with a large wound-care distributor creates an early, diversified revenue channel outside pure R&D. Generating product sales in 2026 would validate commercial viability, support future commercialization planning, and reduce sole dependence on capital markets for funding.
Strengthened Regulatory & Governance ExpertiseAdding a senior advisor with high-level public health and regulatory experience and recent board governance hires improves regulatory strategy and credibility. This durable capability can accelerate development planning, regulatory interactions, and potential labeling or policy advantages over peers.
Bears Say
Accelerating Cash BurnThe step-up in operating and free cash outflows in 2025 signals increasing funding needs and higher execution risk. Over a 2–6 month horizon this structural trend raises the probability management must draw additional tranches, raise equity, or cut activity, affecting program timelines and dilution outcomes.
Pre-revenue With Widening LossesSustained pre-revenue status combined with materially wider operating losses reduces margin visibility and lengthens time to self-sustaining cash generation. The business remains binary on clinical and commercial success, creating durable execution risk for long-term profitability and sustainable margins.
High-cost Secured Financing Risks IPWhile the facility provides runway, its relatively high coupon and security over intellectual property increase long-term financial risk. If milestones slip, the company could face costly interest burdens, potential dilution from conversion features, or loss of IP collateral, impairing future commercial upside.
Turn Therapeutics Inc News
TTRX FAQ
What was Turn Therapeutics Inc’s price range in the past 12 months?
Turn Therapeutics Inc lowest stock price was $2.57 and its highest was $26.50 in the past 12 months.
What is Turn Therapeutics Inc’s market cap?
Turn Therapeutics Inc’s market cap is $99.79M.
When is Turn Therapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Turn Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Turn Therapeutics Inc overvalued?
According to Wall Street analysts Turn Therapeutics Inc’s price is currently Undervalued.
Does Turn Therapeutics Inc pay dividends?
Turn Therapeutics Inc does not currently pay dividends.
What is Turn Therapeutics Inc’s EPS estimate?
Turn Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Turn Therapeutics Inc have?
Turn Therapeutics Inc has 29,788,040 shares outstanding.
What happened to Turn Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Turn Therapeutics Inc?
Currently, no hedge funds are holding shares in TTRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Turn Therapeutics Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
Turn Therapeutics Inc
Global Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. Global Health Solutions, Inc. was incorporated in 2015 and is based in Westlake Village, California.
TTRX Stock 12 Month Forecast
Average Price Target
$6.15
▲(124.45% Upside)
Technical Analysis
AIM ImmunoTech
―
Scinai Immunotherapeutics
―
Pulmatrix
―
Dermata Therapeutics
―
Azitra Inc
―
Ownership Overview
59.05% Insiders
0.12% Mutual Funds
0.11% Other Institutional Investors
40.62% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---